Orexo's Abstral receives two further large EU market approvals in France and Spain

March 2, 2009-- Orexo, announces that AbstralTM has received Marketing Authorisation from the French and Spanish regulatory authorities for the treatment of breakthrough cancer pain.

The details can be read here.